Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| RIO | -0.5% | 59.7 | $ | |
| CMSC | 0% | 23.07 | $ | |
| CMSD | -0.51% | 23.51 | $ | |
| RBGPF | -0.03% | 74.92 | $ | |
| SCU | 0% | 12.72 | $ | |
| RELX | -2.73% | 50.59 | $ | |
| NGG | -0.51% | 72.28 | $ | |
| GSK | -0.96% | 37.32 | $ | |
| SCS | -3.88% | 15.96 | $ | |
| BTI | 0.52% | 55.84 | $ | |
| AZN | -0.15% | 74.48 | $ | |
| RYCEF | -1.19% | 14.33 | $ | |
| BP | 3.3% | 33.6 | $ | |
| VOD | 0.54% | 11.1 | $ | |
| JRI | 0.45% | 13.26 | $ | |
| BCE | 1.06% | 23.56 | $ | |
| BCC | 4.68% | 86.77 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
M.Shukla--MT
